Tscan Price To Book Ratio from 2010 to 2024

TCRX Stock  USD 4.49  0.36  7.42%   
Tscan Therapeutics Price To Book Ratio yearly trend continues to be fairly stable with very little volatility. Price To Book Ratio is likely to outpace its year average in 2024. Price To Book Ratio is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. View All Fundamentals
 
Price To Book Ratio  
First Reported
2010-12-31
Previous Quarter
2.53499554
Current Value
2.66
Quarterly Volatility
7.70787202
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 6.6 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 17.26, Dividend Yield of 0.0 or PTB Ratio of 2.66. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Price To Book Ratio Growth Pattern

Below is the plot of the Price To Book Ratio of Tscan Therapeutics over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Tscan Therapeutics' Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price To Book Ratio10 Years Trend
Slightly volatile
   Price To Book Ratio   
       Timeline  

Tscan Price To Book Ratio Regression Statistics

Arithmetic Mean(10.18)
Coefficient Of Variation(75.71)
Mean Deviation6.80
Median(15.28)
Standard Deviation7.71
Sample Variance59.41
Range17.9391
R-Value0.83
Mean Square Error19.62
R-Squared0.69
Significance0.0001
Slope1.44
Total Sum of Squares831.76

Tscan Price To Book Ratio History

2024 2.66
2023 2.53
2022 0.37
2021 0.67
2020 -6.17

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Price To Book Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Book Ratio 2.53  2.66 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.